Pharmaceuticals

Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion

Agreement includes aggregate upfront and target nomination fees of up to $21.5 million for up to 6 targets, and additional R&D and sales milestones plus tier-based mid-single- to low double-digit royalties. New York , Nov. 8, 2022 /PRNewswire/ -- Insilico Medicine, a clinical stage artificial in...

2022-11-08 22:00 2221

XJTLU and University of Liverpool to inaugurate Joint Centre for Pharmacology and Therapeutics

SUZHOU, China, Nov. 8, 2022 /PRNewswire/ -- On 11 November, Xi'an Jiaotong- Liverpool University (XJTLU) and the University of Liverpool will inaugurate their Joint Centre for Pharmacology and Therapeutics at an online/onsite event in Suzhou,China.

2022-11-08 21:25 2184

Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster

* The Novavax BA.1 vaccine candidate met its primary strain-change endpoint allowing for development of variant vaccines, if necessary * Novavax' prototype vaccine induced broad immune response against original Wuhan, BA.1, and BA.5 strains * The trial showed no benefit for a bivalent vaccin...

2022-11-08 21:00 2877

Traditional Chinese Medicine Lianhua Qingwen Attracted Eyes in the Annual National Conference of Pharmaceutical Society of Nigeria

SHIJIAZHUANG, China, Nov. 8, 2022 /PRNewswire/ -- Recently, the 95th National Annual Conference of the Pharmaceutical Society ofNigeria was held in Jos, capital of Plateau State. The theme of the Conference in this year was "Medicine Security in an Unstable Economy", and more than 3,000 doctors a...

2022-11-08 20:25 1435

BIORCHESTRA announces that BMD-001 reduces Amyloid-β and Tau in non-human primate animal model of Alzheimer's Disease at the RNA Leaders USA Conference in Boston

BOSTON, Nov. 8, 2022 /PRNewswire/ -- Dr. Branden Ryu, CEO and Founder of BIORCHESTRA Ltd. (S. Korea), was a featured speaker at a plenary session of the RNA Leaders CongressUSA in Boston, MA, on October 18th, 2022. Dr Ryu focused on the new efficacy data of their leading compound,BMD-001, derived...

2022-11-08 15:59 1576

Ground-Breaking SIRIUS Endoscope System Is Leading the Next Minimally Invasive Surgical Revolution

Precision Robotics Hong Kong  Home of Next Generation Surgical Robots HONG KONG, Nov. 8, 2022 /PRNewswire/ -- Founded in 2017 and based in Hong Kong Science Park, an innovative robotic start-up company, Precision Robotics ( Hong Kong) Limited (PRHK), has entered a significant milestone with its ...

2022-11-08 15:53 1940

BIORCHESTRA announces that BMD-001 reduces Amyloid-β and Tau in non-human primate animal model of Alzheimer's Disease at the RNA Leaders USA Conference in Boston

BOSTON, Nov. 8, 2022 /PRNewswire/ -- Dr. Branden Ryu, CEO and Founder of BIORCHESTRA Ltd. (S. Korea), was a featured speaker at a plenary session of the RNA Leaders CongressUSA in Boston, MA, on October 18th, 2022. Dr Ryu focused on the new efficacy data of their leading compound,BMD-001, derived...

2022-11-08 15:30 1584

Update on overseas clinical trials progress of novel adjuvant COVID-19 vaccine ReCOV

TAIZHOU, China, Nov. 8, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its primary vaccination Phase II study inthe Philippines and heterologous booster vaccinatio...

2022-11-08 15:17 2064

111 to Announce Third Quarter 2022 Unaudited Financial Results on December 1, 2022 - Conference Call to Follow

SHANGHAI, Nov. 8, 2022 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results ...

2022-11-08 14:09 1572

Sirnaomics Doses the First Patient in Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Aesthetics Treatment

Data results expected to be available in 1H 2023 GAITHERSBURG, Md. and SUZHOU, China, Nov. 8, 2022 /PRNewswire/ -- Sirnaomics Ltd . (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeut...

2022-11-08 05:13 2149

Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO, Nov. 7, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster presentation fro...

2022-11-07 23:25 2324

Lunit Highlights the Effectiveness of AI in Acceleration of Immunotherapy Research--Findings to be Presented at SITC 2022

* Lunit to present three abstracts featuring Lunit SCOPE IO, the company's AI biomarker for immune phenotyping. * Lunit's presentations this year will highlight the effectiveness of Lunit SCOPE IO in accelerating immunotherapy clinical trials and drug development. SEOUL, South Korea, Nov. 7, ...

2022-11-07 21:00 1760

Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris, Completed the First Patient Dose in Phase III Trial

SHANGHAI, Nov. 6, 2022 /PRNewswire/ -- Asieris Pharmaceuticals, a global biopharmaceutical company specializing in the discovery and development of innovative drugs for the treatment of genitourinary tumors and other major diseases, announced that Hexvix®, a drug used for the diagnosis for bladde...

2022-11-07 10:04 1373

Ascletis Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022

HANGZHOU and SHAOXING, China, Nov. 7, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today that the abstract of a Phase I, Single-Dose Study of ASC43F for non-alcoholic steatohepatitis (NASH) has been reported at The Liver Meeting® 2022 of the American Association for...

2022-11-07 08:10 2010

Innovent Releases Results of a Phase 3 Clinical Study of Tafolecimab(IBI306)in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022

ROCKVILLE, M.D. and SUZHOU, China, Nov 7, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and o...

2022-11-07 08:00 2712

Brexogen's Exosome Therapy for Atopic Dermatitis, 'BRE-AD01' Accepted for Phase 1 Clinical Trials by US FDA

First entry to clinical trial of exosome for atopic dermatitis The first exosome-based therapeutics in US clinical trial among Korean companies SEOUL, South Korea, Nov. 7, 2022 /PRNewswire/ -- The US FDA granted the initiation of the phase 1 clinical trial of 'BRE-AD01', an exosome- based ther...

2022-11-07 07:00 1873

Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study

Summary of Study Outcomes * ZIRCON Phase III study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) has met all of its primary and secondary endpoints * The study delivered co-primary endpoints of 86% sensitivity and 87% specificity and 93% posit...

2022-11-07 06:48 1654

Certa Therapeutics' investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases

* Research presented today by University of Michigan Medical School highlights FT011's ground-breaking treatment potential from human expression profiles in chronic kidney disease study supported by animal model data * The research demonstrated that treatment with FT011 results in a remarkable...

2022-11-04 20:00 2184

Fosun Participates in the CIIE for the Fifth Consecutive Year with the Debut of Innovative Products in China

HONG KONG, Nov. 4, 2022 /PRNewswire/ -- The 5th China International Import Expo (hereinafter referred to as the "CIIE") will be held inShanghai from 5 November to 10 November. Fosun will participate in the CIIE for the fifth consecutive year with its overseas member companies and partners from th...

2022-11-04 14:43 3675

NSW Health & Cicada Innovations celebrate Australia's biggest health startup training program with 1.1k participants in first year

SYDNEY, Nov. 4, 2022 /PRNewswire/ -- The NSW Health Commercialisation Training Program  (CT Program), delivered by Aust...

2022-11-04 11:35 2465
1 ... 102103104105106107108 ... 295